These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 36505496)

  • 1. Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma.
    Chen M; Nie Z; Huang D; Gao Y; Cao H; Zheng L; Zhang S
    Front Immunol; 2022; 13():1048204. PubMed ID: 36505496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma.
    Zhang L; Chen Y; Hu W; Wu B; Ye L; Wang D; Bai T
    Front Immunol; 2023; 14():1230267. PubMed ID: 37600792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of an immunogenic cell death-related gene signature predicts survival and sensitivity to immunotherapy in clear cell renal carcinoma.
    Zhou S; Lu Y; Chen Y; Gan W
    Sci Rep; 2023 Mar; 13(1):4449. PubMed ID: 36932108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
    Chen Y; He J; Jin T; Zhang Y; Ou Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A polyamine metabolism risk signature for predicting the prognosis and immune therapeutic response of kidney cancer.
    Li B; Kong Z; Liu Y; Xu B; Liu X; Li S; Zhang Z
    Transl Cancer Res; 2023 Oct; 12(10):2477-2492. PubMed ID: 37969387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
    Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
    Front Immunol; 2022; 13():934243. PubMed ID: 36189255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of LD-related genes signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Jia Y; Dong X; Yang F; Zhou L; Long H
    BMC Nephrol; 2024 Sep; 25(1):298. PubMed ID: 39256647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyroptosis-Related Subtypes Predict the Response of Clear Cell Renal Cell Carcinoma to Targeted Therapy.
    Ma J; Kang Z; Yang G; Wang X; Si M; Wang Y; Li G; Bai S; Zeng F; Li M; Wang Z; Wang L; Xu W
    Front Biosci (Landmark Ed); 2023 Dec; 28(12):334. PubMed ID: 38179741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma.
    Wang Y; Zheng XD; Zhu GQ; Li N; Zhou CW; Yang C; Zeng MS
    Front Immunol; 2022; 13():861328. PubMed ID: 35479084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosome-related lncRNA score: A value-based individual treatment strategy for predicting the response to immunotherapy in clear cell renal cell carcinoma.
    Yang Z; Zhang X; Zhan N; Lin L; Zhang J; Peng L; Qiu T; Luo Y; Liu C; Pan C; Hu J; Ye Y; Jiang Z; Liu X; Sun M; Zhang Y
    Cancer Med; 2024 Jun; 13(11):e7308. PubMed ID: 38808948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of prognostic and tumor microenvironment characteristics of necroptosis index and BIRC3 in clear cell renal cell carcinoma.
    Wei K; Zhang X; Yang D
    PeerJ; 2023; 11():e16643. PubMed ID: 38130918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma.
    Zhang D; Ni Y; Wang Y; Feng J; Zhuang N; Li J; Liu L; Shen W; Zheng J; Zheng W; Qian C; Shan J; Zhou Z
    J Transl Med; 2023 Jul; 21(1):489. PubMed ID: 37474942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a Seven-Gene Signature Associated with CD8
    Chen Y; Zhou X; Xie Y; Wu J; Li T; Yu T; Pang Y; Du W
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering glutamine metabolism patterns for malignancy and tumor microenvironment in clear cell renal cell carcinoma.
    Wu G; Li T; Chen Y; Ye S; Zhou S; Tian X; Anwaier A; Zhu S; Xu W; Hao X; Ye D; Zhang H
    Clin Exp Med; 2024 Jul; 24(1):152. PubMed ID: 38970690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SAA1 Has Potential as a Prognostic Biomarker Correlated with Cell Proliferation, Migration, and an Indicator for Immune Infiltration of Tumor Microenvironment in Clear Cell Renal Cell Carcinoma.
    Xu Z; Wu Y; Fu G; Chen X; Sun J; Tian J; Jiang P; Wang Y; Jin B
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Validation of UPF1 as a Novel Prognostic Biomarker in Renal Clear Cell Carcinoma.
    Wu C; Li H; Chang W; Zhong L; Zhang L; Wen Z; Mai S
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36421841
    [No Abstract]   [Full Text] [Related]  

  • 18. Construction of an interferon regulatory factors-related risk model for predicting prognosis, immune microenvironment and immunotherapy in clear cell renal cell carcinoma.
    Pan H; Lu W; Zhang M; Liu C
    Front Oncol; 2023; 13():1131191. PubMed ID: 37182129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
    Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
    BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma.
    Bao W; Han Q; Guan X; Wang Z; Gu M
    Oncol Res; 2023; 31(2):181-192. PubMed ID: 37304236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.